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Abstract
Objective: To evaluate the relationship between compliance and persistence with glatiramer acetate (GA) and
the behavioral variables in the transtheoretical model of change.
Methods: Patients diagnosed with relapsing-remitting multiple sclerosis and being treated with GA for the first
time, whether treatment-naïve (TN) or treatment-experienced (TE), were eligible for this prospective, observational,
12-week study. Institutional Review Board approval was obtained for each of 32 US study sites, and written informed
consent was obtained for all patients prior to study procedures. Four office visits were required. Study procedures
included baseline self-injection training and patient-reported behavioral variable surveys. Injection competence and
medication compliance and persistence were assessed at weeks 4 and 12.
Results: A total of 257 patients were enrolled; 80.9% were female, 81.6% white, and 60.0% TN. The evaluable
population included 146 TN patients and 88 TE patients having discontinued beta-interferons. TE patients were at a
significantly higher readiness stage, were less concerned about the negative aspects of self-injection, but had lower
levels of MS self-efficacy than TN patients. While compliance and persistence rates did not differ between TN and
TE groups, there were differences in outcome predictors. For the TN patients both higher self-injection competence
at baseline and improvement in self-injection competence over the first month of therapy were predictive of better
compliance and persistence with GA. Separate from injection competence, higher levels of functional self-efficacy
were directly associated with better persistence in TN patients. None of the behavioral variables appeared to predict
compliance or persistence for the TE patients.
Conclusion: Among the TN, injection competency at baseline and improvement over the first month of use were
significant predictors of compliance and persistence to GA at 12 weeks.Improving self-injection competence should
be a priority when planning interventions for TN patients. Behavioral factors predicting compliance and persistence
among TE patients require further study. ClinicalTrials.gov (number NCT00238654)
Keywords: Compliance; Persistence; Injection readiness; Self-
injection; Self-efficacy; Injection competence; Transtheoretical model;
Multiple sclerosis; Glatiramer acetate; Beta-interferon
Introduction
Compliance and persistence with continuous, life-long therapy for a
chronic condition can be difficult for patients, regardless of the
specific therapy employed or condition under treatment. Compliance
with medication refers to the extent that a patient adheres to the
timing, dosage and frequency prescribed by the physician, while
persistence is the “act of continuing the treatment for the prescribed
duration [1].“ The problem of enlisting continued patient cooperation
with prescribed therapies requiring self-administration is the most
significant threat to the effectiveness of these therapies. When
medications must be injected, as is the case with many of the disease-
modifying therapies for multiple sclerosis (MS) adherence and
compliance may be a barrier to use.
The most common type of multiple sclerosis (MS) is relapsing-
remitting; in which patients have episodes of worsening neurologic
function, followed by full or partial recovery [2]. Treatment with
disease-modifying therapies decreases frequency and severity of
relapses and reduces brain lesion development, which in turn may
slow disease progression. The Medical Advisory Board of the National
Multiple Sclerosis Society recommends that treatment with one of
these agents should begin immediately after a definitive diagnosis of
relapsing-remitting MS (RRMS) and may also be considered for
selected patients with a first attack who are at high risk of MS.
Treatment should be continued indefinitely unless there is poor
effectiveness or tolerability [3].
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The requirement that a disease-modifying MS therapy be self-
injected is not the only barrier to treatment compliance and
persistence, but may be one of the most daunting for many patients.
The injections may be perceived as painful or difficult to perform and
patients may experience injection anxiety [4]. Physical impairments
associated with MS such as poor hand-eye coordination, tremor, and
fatigue may in fact increase the difficulty of performing self-injection,
and cognitive deficits may impair the patient’s ability to learn the best
injection technique [5]. These factors and others may influence
patients to decide that they are unwilling or unable to self-inject.
Despite patients’ reservations about self-injecting treatment,
research has demonstrated that persistence is improved when patients
self-inject as opposed to receiving treatment from another individual,
whether at home or in the clinic [4]. Thus patients should be
encouraged to learn self-injection techniques, as long as they are
physically able to perform them, in order to increase the probability of
long-term compliance and persistence.
Because of the importance of regular, continuous treatment for MS
and the potential barriers to treatment with a subcutaneous injectable
like glatiramer acetate (GA, Copaxone®, Teva Pharmaceutical
Industries), we developed a study model to conceptualize and predict
behavioral factors that would influence patients’ adoption of, and
compliance and persistence with self-injected GA for RRMS. This
paper will describe the assessment of the model variables in predicting
compliance and persistence with GA.
The Study Model
The Transtheoretical Model of Readiness to Change
The study model was predicated on the transtheoretical
model (TTM) developed by Prochaska and DiClemente, which
conceptualizes intentional behavioral change as a process involving
movement through a series of 5 discrete stages that define the
“readiness” to adopt a new behavior: i.e., precontemplation,
contemplation, preparation, action, and maintenance [6-8]. In this
model, processes of change are the covert and overt activities that
people use to progress through the stages [9]. Knowledge of the
individual’s current stage has critical implications for successful
intervention because stagespecific interventions accelerate a patient’s
movement through earlier stages towards action and maintenance of a
desired behavior. The TTM has been the basis for developing various
instruments that measure stages of change for different health
behaviors and effective interventions to promote health behavior
change. The strongest empirical database for the model exists for the
topic of smoking cessation; however, other areas, such as engaging in
an exercise program, weight control, reducing high-fat diets, and
medical compliance have also been investigated using this model [7,8].
Specific to MS, Holland et al. proposed that the TTM of behavioral
change could be useful in achieving treatment goals [10].
Because our intent was to focus specifically on the adoption of self-
injection of GA, we adapted Prochaska’s TTM of intentional change
for self-injection. Table 1 identifies, in behavioral terms, the person’s
current stage of change with respect to selfinjection, the processes of
change, and interventions to facilitate change. While we believed that
readiness to selfinject would have an impact on compliance and
persistence with therapy, we also hypothesized that intervening
variables might be more directly associated with compliance and
persistence to therapy. Borrowing from other elements of the TTM, 3
potential intervening behavioral variables were identified for this
study: (1) selfreported decisional balance (pros and cons of self-
injection); (2) selfreported self-efficacy; and (3) selfinjection
competence as evaluated by the nurse. Figure 1 depicts the proposed
relationship among the behavioral variables and adherence in our
study model.
Figure 1: The study model for compliance and persistence to self-
injected MS therapy: proposed relationships among behavioral
variables and compliance and persistence
Stage of Change Description
Processes of Change Interventions
Precontemplation
(Stage 1)
No intention of learning to selfinject in the foreseeable future (i.e., the next 6 months).
Patients may be in this stage because they are uninformed or underinformed about the consequences of selfinjecting or they may
have tried to start selfinjecting a number of times and become demoralized about their ability to do so.
Patients in this stage are often characterized as resistant or unmotivated or as not ready to become selfinjectors.
Consciousness Raising Discussion about RRMS: how it affects the body and the case for treatment.
Discussion about the pros (not cons) of selfinjection.
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Written information about MS and its treatment.
Dramatic Relief Recommend Shared Perspectivesa
Contemplation (Stage 2) Patients are developing awareness of the need for selfinjection and are seriously considering selfinjecting in the next 6 months.
Patients in this stage are more aware of the pros of selfinjecting but are also acutely aware of the cons. This balance between the
costs and benefits of changing can produce profound ambivalence that can keep patients stuck in this stage for long periods of
time (i.e., chronic contemplation or behavioral procrastination).
These patients are not yet ready to become selfinjectors.
Self-Reevaluation Discussion about what is required to selfinject.
Demonstration of selfinjection.




Patients are intending to begin selfinjecting in the immediate future (i.e., the next 4 weeks).
Patients in this stage have typically taken some significant action towards selfinjecting in the past year and they have a plan of
action, such as talking to their physician or nurse.
These are the people that should be recruited to become selfinjectors.
Self-Liberation Setting an appointment to initiate selfinjection.
Viewing the glatiramer acetate therapy information video.
Reading the written information in the glatiramer acetate therapy information kit.
Selfinjection training, followed by observed selfinjection, with coaching as needed.
Action
(Stage 4)
Patients have started to selfinject within the past 6 months.
In the action stage, patients have started to selfinject but selfinjection is being performed at a minimally acceptable level and the
patient is not yet at ease with selfinjection.
The Action stage is the stage where vigilance against relapse is critical.
Contingency Management Review of selfinjection training and handson practice followed by observed selfinjection, with
coaching as needed.
Encouraging repeated daily selfinjection to build mastery of the technique.
Maintenance
(Stage 5)
Patients may be considered ‘long-term selfinjectors’.
Patients are consistently engaging in selfinjection and are integrating selfinjection into their daily routine.
Maintenance is the stage in which patients are less likely to relapse and increasingly more confident that they can continue
selfinjection.
Helping Relationships Review of glatiramer acetate therapy information video.
Discussion about the pros and cons of selfinjection.
Professional nurse calls (Shared Solutions®).
Table 1: The Transtheoretical Model’s Stages of Change to SelfInject and Processes of Change, aPatients who were deciding whether to begin
therapy were offered the opportunity to contact a peer with MS (a volunteer) who had relevant experience with injecting glatiramer acetate.
Intervening Behavioral Variables Associated with
Compliance and Persistence
Decisional Balance
Part of the decision to move from one stage of readiness to the next
is based on the relative weight given to the pros and cons of changing
behavior, in this case, moving from no selfinjection to selfinjection
several times a week. There is evidence that pros and cons are
indicators of an individual’s progress from pre contemplation to
contemplation and preparation [11-13]. In general, the pros are
expected to increase as a function of readiness stage whereas the cons
will decrease with a crossover around the contemplation or
preparation stage, depending upon the health behavior examined.
Self-efficacy
Selfefficacy is the belief in one’s capabilities to organize and execute
the action required to manage prospective situations [14]. Bandura’s
concept applies to individuals facing behaviors or tasks they perceive
as novel, unexpected, or stressful. Bandura proposed that if a person is
given sufficient motivation to engage in a behavior, it is the person’s
selfefficacy beliefs that will determine whether that behavior will be
started, how much effort will be expended, and how long the effort will
be sustained in the face of obstacles and negative experiences.
Individuals with stronger selfefficacy are more likely to select
challenging tasks, to persist at them longer, and to perform them
successfully. According to Bandura, self-efficacy is the highest
predictive factor of perseverance in a new behavior. There is
considerable evidence that higher selfefficacy is related to greater
persistence in diverse contexts ranging from health recommendations
for management of diabetes and rheumatoid arthritis, to exercise and
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smoking cessation programs, to medication taking in a variety of
diseases such as epilepsy, HIV, post-transplantation [15] and RRMS
[4,16].
Self-Injection Competence
Patients must be physically and mentally capable of performing an
injection in order to initiate and maintain self-injections. Training in
self-injection techniques is important during the contemplation,
preparation, and action stages of change. To simplify selfinjection, an
auto injector device (autoject®2 for glass syringe) and prefilled syringes
of GA were used in this study.
Methodology
Patients diagnosed with RRMS and being treated with GA for the
first time, whether treatment-naïve (TN) or treatment-experienced
(TE), were eligible for this prospective, observational, 12-week study
(READY Trial). IRB approval was obtained for each of 32 US study
sites and written informed consent was obtained for all patients in the
volunteer sample prior to study procedures. The study was listed on
ClinicalTrials.gov (NCT00238654).
Four office visits were required. All enrolled participants were also
required to enroll in the Shared Solutions® program for assistance and
support during treatment with GA. Study procedures included self-
injection training at initiation of GA treatment and patient-reported
surveys at each visit. Injection competence evaluation and medication
compliance and persistence were assessed at weeks 4 and 12. A





The Readiness Survey, a 16-item TTM-derived instrument, assessed
intentions and current selfinjection activities with respect to self-
injection of GA. The survey asked the patient to rate each item using a
5point scale, where 1 was “strongly disagree” and 5 was “strongly
agree”. An algorithm was devised to arrive at a score for each stage of
change and the patient was assigned to the stage with the highest score.
Decisional Balance Inventory
The Decisional Balance Inventory was developed to assess positive
and negative aspects (pros and cons) of selfinjection. The survey asked
the patient to rate 10 items according to their importance to the
patient, using a 5point scale where 1 was “not important” and 5 was
“extremely important”. The inventory yielded two scores, obtained by
summing the ratings for the pro and con items separately. Each of
these scores ranged from 525. High pro scores and low con scores
indicated a favorable attitude toward self-injection. A combined score
was obtained by subtracting the con score from the pro score. The
combined score thus ranged from 20 to +20 with a higher positive
score indicating a more favorable attitude toward selfinjection.
MS SelfEfficacy (MSSE) Scale
The MSSE scale a core construct of the TTM, assesses patients’
personal convictions that they will be able to perform specific
behaviors in a given situation [18]. It has been shown to be positively
related to adherence (persistence) to GA [15,16, 19].
The MSSE scale consisted of two subscales of nine items each,
relating to function and control. Patients were asked to rate each item
according to how certain they felt that they would be able to perform
the behavior (i.e., dressing, taking care of the home) or control the
situation (i.e., control disease symptoms, reactions to disease-related
limitations) described in the item. Each item was rated on a scale from
10 to 100, where 10 were “very uncertain” and 100 was “very certain”.
Each subscale score ranged from 90 to 900, with higher scores
denoting certainty. The two parts of the scale were scored and
reported separately; a combined score was obtained by adding the
function score and the control score
SelfInjection Competence
Measurement of the targeted behavior is also a key component of
the TTM; therefore, a study nurse evaluated the competence with
which the patient performed selfinjection using the SelfInjection
Technique Evaluation form designed for this study. Selfinjection
competence was rated on a 10point scale ranging from 1 to 10, with
“1” representing “poor” and “10” representing “excellent”. The form
also allowed the rater to check off the key steps that a patient followed
for the selfinjection and to note any barriers to learning; however, the
score was based on the global competence rating only.
Compliance and Persistence Measures
Compliance was defined by the number of prefilled syringes that
were used over the course of the treatment period since the preceding
visit. Since the length of time between visits varied, this number was
adjusted to the length of the period to yield a “percentage of days
compliant.”
Persistence was evaluated on the basis of responses to two
questions: 1) “Has the patient used the study therapy continuously for
the past month [or two months]?” and 2) “If the patient stopped
therapy, is the patient willing to restart?” If the patient stopped therapy
for a short time during the prior period in question but was willing to
restart at this office visit, the subject was considered persistent.
Statistical Analysis
Demographic, disease-related, and behavioral characteristics were
compared between patient groups (i.e., TN vs. TE) at the inception of
the READY trial. Between-group comparison was performed using a t-
test for independent sample means for continuous variables (e.g., age,
length of illness, Decisional Balance Inventory scores) or using the
Mann-Whitney U test for ordinal variables (e.g., Readiness stage). Chi-
square was used to compare the groups on categorical variables such as
gender and ethnicity. Additionally, Chi-square and Fisher’s Exact Test
were used to compare persistence/non-persistence for the TN versus
the TE group at the 4 and 12 week visits. Forward stepwise logistic
regression analyses were used to assess the relationship between all of
the variables and membership in each dichotomous group.
A multiple-group path analysis using LISREL 8.71 software was
performed to evaluate the direct and indirect influences of background
variables and behavioral variables on compliance and persistence at 12
weeks. The external variables included in this analysis were those
background variables shown to be related to compliance and
persistence by the prior analyses or by the compliance and persistence
literature.
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Results
Demographic and Disease-Related Characteristics
Two hundred and fifty-seven patients were enrolled in the study
and included in the intent-to-treat population. The majority was
female (80.9%) and White (81.6%), as is consistent with the MS
population in general [20-22]. The patients ranged in age from 19 to
69 years (Mean [M] = 43.7; Standard Deviation [SD] = 10.6). Age at
diagnosis ranged from 18 to 61 years (M = 39.6; SD = 10.2), and
duration of MS ranged from less than a year to 29 years (M = 4.1; SD =
6.0). Since patients were recruited, for the most part, from community
neurology clinics where Expanded Disability Status Scale (EDSS)
assessment is not routinely done, investigators were asked to record
the most recent EDSS scores from the charts, if available. Last recorded
EDSS scores were available for 63 of the patients; these ranged from 0
to 7 (Median (Mdn) = 1.5). Sixty percent of patients (155/257) were
TN. Among the 102 patients who had been previously treated,
interferon beta-1a IM was the most common first-line treatment
(received by 54.9%), followed by interferon beta-1b SC, (received by
34.3%). Poor tolerability was the primary reason for previous
treatment discontinuation. Flu-like symptoms, mood disorders, and
hepatobiliary intolerance were the most commonly reported adverse
events.
Comparisons between Treatment-Naïve and Treatment-
Experienced Patients
Table 2 provides a comparison of the TN patients and TE patients
in terms of each of the variables in this study. TE patients were
somewhat older, had been diagnosed at a younger age (p< .05), had a
longer duration of MS (p< .001), and were more disabled (p< .001,
among the subset of patients who had an EDSS score).
Readiness Stage
At the inception of the study, the readiness stage tended to be
higher for TE patients (Mdn = 3.0) compared with TN patients (Mdn
= 2.0, p< .001). The majority of TN patients were in the contemplative
stage (57.8%) as compared with only 39.0% of the TE patients (Figure
2). Nearly one quarter of TE patients were in the action or
maintenance phases because of their recent experience injecting a
beta-interferon therapy. The single TN patient who was in the action
























































































































































































Table 2: Baseline Characteristics: Treatment-Naïve vs. Treatment-
Experienced Patients M = Mean; SD = Standard Deviation; Mdn =
Median; aBased on chi-square and Fisher’s Exact Test. bIncludes 15
African-American, 9 Hispanic, 1 Native American, and 1 “Other”
patient. cIncludes 16 African-American, 2 Hispanic, 2 Native
American, and 1 Asian patient. dBased on independent t test. eBased
on Mann-Whitney U test
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Figure 2: Readiness stage at baseline for the treatment-naïve, treatment-experienced, and total patient (combined) groups. Median readiness
stage was higher in the treatment-experienced group than in the treatment-naïve group (p< .001).
Decisional Balance, MS Self-Efficacy, and Self Injection
Competence
The two groups also differed on decisional balance and MS self-
efficacy at baseline. TN patients had significantly higher con scores on
the Decisional Balance Inventory than the TE patients (p = .03), but
did not differ on the pro or combined scores. TN patients also had
significantly higher scores on the function, control, and combined
scales of the MSSE (p< .001). Mean scores on self-injection
competence at baseline did not differ between the TN and TE groups.
Of the 257 enrolled patients, 234 (91.1%) actually initiated therapy
with GA and had post-baseline data reported; 146 were TN and 88
were TE. There were 32 patients who did not complete the 12 weeks of
the study and represented the non-persistent patients (13.7%) in the
study. The most common reasons for stopping therapy included
patient’s decision to stop (12), adverse experiences (7), and loss to
follow-up (6). There were 202 persistent patients (86.3%) who
completed the 12 weeks of study. The percentage of days compliant
with GA during the first month of therapy was 95.7% and it improved
over the 12 weeks to 97.4%.
Table 3presents the compliance and persistence results at 4 weeks
and 12 weeks. There were no statistically significant differences in
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Table 3: Compliance and Persistence, M = Mean; SD = Standard
Deviation; Mdn = Median; 1 Of the 257 subjects who were enrolled in
this study, 23 subjects discontinued the study prior to starting
glatiramer acetate treatment.
Regression Analysis
Prior to path analysis model building, two preliminary stepwise
analyses were performed to identify the best overall predictors of
compliance and persistence. Logistical regression analysis was applied
to the persistence outcome and multiple regression analysis was
applied to the compliance outcome. All of the demographic, disease-
specific and behavioral variables were included in these regressions.
Preliminary analysis showed the combined Decision Balance score to
have better predictive power than the individual pro and con scores,
and therefore, only the combined score on this inventory was used. In
contrast, on the basis of similar preliminary analyses, the control and
function scores, but not the combined scores from the MSSE were
included. The first analysis yielded three significant predictors of
persistence to GA: (1) duration of MS; (2) injection competence at
baseline; and (3) change in injection competence at 1 month. Longer
duration of MS, higher injection competence at baseline, and positive
change in injection competence at 1 month was associated with
membership in the persistent group. The second analysis yielded
significant predictors for compliance with GA: (1) higher pro
decisional balance; (2) higher injection competence at baseline; and (3)
being female. Persons who were TN were less compliant than persons
who were TE.
Figure 3: Predictive pathways that were significant in the treatment-
naïve and treatment-experienced groups.
Path Analysis
Figure 3 presents the results of the path analyses that predict
compliance with and persistence to GA for the TN and TE groups. The
values next to each line of prediction are the standardized regression
estimates. The values next to the double-head lines linking compliance
and persistence are the correlations between these two factors after
controlling for the regression effects. This correlation showed marked
differences between the TN and TE groups. In the TN group,
compliance and persistence showed a strong positive correlation while
this correlation was moderately negative in the TE group.
A number of noteworthy relationships emerged from the path
analysis. First, for the TN group, both baseline injection competence
and the change in injection competence at 1 month were significant
predictors of compliance and persistence with GA. The change in
injection competence at 1 month served as a mediator of the effects of
decision balance as well as the effect of gender on compliance and
persistence in the TN group. Independent of injection competence,
higher levels of functional self-efficacy were directly associated with
better persistence in TN patients. In the TE group neither injection
competence nor self-efficacy had an effect on compliance and
persistence with GA.
Discussion
The study model presented here was developed to investigate the
behavioral factors that may be influencing compliance and persistence
to self-injected GA. Analysis of disease-related characteristics and
behavioral variables revealed baseline differences between patient
groups. As might be expected, TE patients had a longer duration of
MS, and for those with EDSS scores available, it appears that they may
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have had higher disability levels than TN patients. TE patients were
also diagnosed with MS at a younger age. Differences in behavioral
variables appeared to reflect differences in the length of experience
with injectable treatment and with MS in general. TE patients were at a
higher stage of readiness at baseline - probably due to their past
experiences with self-injection. However, their scores on self-efficacy
(MSSE) were lower than those of TN patients. The lower self-efficacy
scores among the TE patients may be related to the length of their MS
experience and how well they have been able to cope with the disease
in general; symptoms and uncertainty are hallmarks of MS and having
lived with them for a number of years they had knowledge of MS that
was considerably greater than those who were TN. In addition, the TE
patients had been self-injecting but had to discontinue and change
therapy due to intolerance or suboptimal effectiveness. Their self-
injection competence at baseline was no better than that of the TN
patients. The experience of having to discontinue one of a limited
number of treatments available to them may have contributed to the
lower self-efficacy of some TE patients. They may have been uncertain
about how they would respond to the new therapy, and in turn, they
may have questioned whether they would be able to manage their
symptoms in order to participate in daily activities. Scores on the con
portion of the Decisional Balance Inventory at baseline were consistent
with readiness stage scores in that TN patients held less favorable
attitudes towards self-injection than TE patients – again, possibly
reflecting differences in experience with injections.
The results of the path analyses suggest that for the TN group,
either starting out with injection competence or gaining that
competence within the first month of therapy with GA is an important
accomplishment that cans predict compliance and persistence at 12
weeks. Those who are lower on injection competence at the beginning
of therapy with GA or do not develop it within the first month may
not be resilient enough to comply with the injection regimen.
However, for those who are TN and do not have high levels of
injection competence at the beginning of therapy, positive decisional
balance can compensate and lead to increases in the level of injection
competence at 1 month. Furthermore, quite separate from injection
competence, higher levels of functional self-efficacy are directly
associated with better persistence in TN patients.
The prediction of compliance and persistence with GA in the TE
group was much less successful than in the TN group. None of the
behavioral variables examined in the present study emerged as
significant predictors of compliance or persistence. This unsuccessful
outcome is consistent with clinical impressions that compliance and
persistence encompass more complicated issues for patients who have
experienced previous treatment failures. Further investigation of this
topic is needed.
The READY Trial was a prospective observational study and that
poses some methodological limitations as recently discussed by Marrie
[23]. Lack of randomization is commonly cited but it is an inherent
feature of observational studies. Lack of standardized data collection is
sometimes a limitation of observational studies; however, the READY
Trial was designed around standardized case report forms that assured
data for each patient was recorded using the same questions at each
office visit and over time.
While not directly assessed in this study, disability may be a
potentially important characteristic to differentiate TN from TE
patients and should be assessed comprehensively in future studies.
Patients provided self-reports about their persistence to therapy,
though patients were instructed to bring unused medication syringes
to each visit that offered an objective measure of drug compliance. A
high rate of persistence and compliance achieved by both treatment
groups in this study limited the variability of the outcome measure and
may have reduced the opportunity to identify predictors of these drug
use outcomes.
Our original model in which the behavioral variables, decisional
balance and MS self-efficacy functioned in a mediating role between
injection readiness and compliance and persistence with GA was not
supported. The readiness variable itself was not a predictor for either
the TN or the TE groups. However, injection competence at the
beginning of therapy and improved injection competence over the first
month of therapy were significant predictors of compliance and
persistence at 12 weeks among the TN group of GA users. In addition,
in the absence of high injection competence at the beginning of
therapy, high decisional balance scores predicted increases in injection
competence at 1 month for TN patients on GA therapy. Higher
functional self-efficacy scores were directly associated with better
persistence to GA.
In summary, for those patients with RRMS who are being treated
with GA, long-term compliance and persistence is a necessity in order
to reduce the number and severity of relapses and potentially slow MS
progression. If clinicians are able to convince patients about the
benefits of treatment and can motivate them to begin treatment, it will
enhance patients’ functional self-efficacy. Patients need to know what
will be required of them to maintain treatment with GA, and self-
injection training and support early in treatment will be helpful in
shifting their decisional balance from negative to positive and building
their injection competence. Due to the long-term treatment required
for MS, ongoing patient encouragement from clinicians to continue
treatment with GA despite any obstacles they may face will be keenly
important for patients’ long-term compliance and persistence with
GA.
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